hrcak mascot   Srce   HID

Review article

Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology

Zvjezdana Špacir Prskalo   ORCID icon orcid.org/0000-0002-4519-8183 ; Department of Medical Biochemistry in Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Mihaela Gaće ; Department of Medical Biochemistry in Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Sanja Dobrijević ; Department of Medical Biochemistry in Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ljiljana Mayer ; Department of Medical Biochemistry in Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Fulltext: english, pdf (154 KB) pages 9-14 downloads: 83* cite
APA 6th Edition
Špacir Prskalo, Z., Gaće, M., Dobrijević, S. & Mayer, Lj. (2015). Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology. Libri Oncologici, 43 (1-3), 9-14. Retrieved from https://hrcak.srce.hr/189799
MLA 8th Edition
Špacir Prskalo, Zvjezdana, et al. "Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology." Libri Oncologici, vol. 43, no. 1-3, 2015, pp. 9-14. https://hrcak.srce.hr/189799. Accessed 20 Sep. 2019.
Chicago 17th Edition
Špacir Prskalo, Zvjezdana, Mihaela Gaće, Sanja Dobrijević and Ljiljana Mayer. "Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology." Libri Oncologici 43, no. 1-3 (2015): 9-14. https://hrcak.srce.hr/189799
Harvard
Špacir Prskalo, Z., et al. (2015). 'Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology', Libri Oncologici, 43(1-3), pp. 9-14. Available at: https://hrcak.srce.hr/189799 (Accessed 20 September 2019)
Vancouver
Špacir Prskalo Z, Gaće M, Dobrijević S, Mayer Lj. Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology. Libri Oncologici [Internet]. 2015 [cited 2019 September 20];43(1-3):9-14. Available from: https://hrcak.srce.hr/189799
IEEE
Z. Špacir Prskalo, M. Gaće, S. Dobrijević and Lj. Mayer, "Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology", Libri Oncologici, vol.43, no. 1-3, pp. 9-14, 2015. [Online]. Available: https://hrcak.srce.hr/189799. [Accessed: 20 September 2019]

Abstracts
Ovarian cancer is, with its high incidence and mortality, a worldwide problem. One reason for this is the lack of symptoms. The second reason is practically non-existant screening for ovarian cancer. Until recently, the only routinely used marker for ovarian abnormalities was CA125. Determination of HE4 levels, together with those of CA125 and the
calculation of the ROMA index, is a suitable method for improving primary detection of ovarian cancer. The measurement of serum HE4 is a useful method for diff erential diagnosis between benign gynecologic disease and ovarian cancer.

Keywords
ovarian cancer; CA125; HE4 (Human epidydimis protein); ROMA (Risk of Ovarian Malignancy Algorithm) index

Hrčak ID: 189799

URI
https://hrcak.srce.hr/189799

[croatian]

Visits: 137 *